Highly effective prevention of myocardial infarction: Benefits of influenza vaccination

The Influenza vaccination After Myocardial Infarction (IAMI) trial is a pivotal, multicenter, randomized, double-blind, placebo-controlled study designed to assess the clinical benefit and safety of influenza vaccination in the immediate post–myocardial infarction (MI) period. The trial enrolled high-risk patients presenting with acute coronary syndromes (both STEMI and NSTEMI), randomizing them within 72 hours of coronary angiography or percutaneous coronary intervention (PCI) to in-hospital influenza vaccination or placebo. Primary composite endpoint The primary endpoint was the composite of all-cause death, recurrent MI, or stent thrombosis at 12 months post-randomization. Influenza vaccination resulted in a statistically significant reduction in the primary endpoint events: 5.3% in the vaccine group versus 7.2% in the placebo group (hazard ratio [HR] 0.72, 95% CI 0.52–0.99; p=0.040). This finding translates to a 28% relative risk reduction, with an absolute risk reduction of about 2% for the composite outcome. 1. Major secondary endpoints All-cause mortality: Rates were 2.9% in the vaccine group...